ProStrakan/Orexo extend license for Rapinyl to North America as Endo pulls out
The Scottish ProStrakan Group has extended its European licensing agreement with Sweden's Orexo for cancer pain drug Rapinyl/Abstral (fentanyl) to cover North America after the region's former licensee, Endo Pharmaceuticals, returned rights to the drug. ProStrakan will commit to upfront and certain regulatory and sales milestones totalling $29.0 million, including a $2.0 million signing fee. As a result, existing milestones for Europe will change from 5.0 million euros ($7.9 million) to $5.0 million and royalties for both regions will increase 7%-9%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze